How do new developments in machine learning support scalability in genomic research? Our latest white paper covers developments in AI and genomics, as well as our clinical validation study of AION, our AI-driven platform supporting variant interpretation scientists.
Read more on the clinical validation of AION on the Genomics England 100.000 Genomes Project. Simply fill out the form and have the white paper delivered to your inbox.
Genome sequencing has the potential to resolve rare undiagnosed diseases. Yet, modern genomic tests do not lead to a diagnosis for every patient. Many patients undergo a diagnostic odyssey prolonged by the challenge of reviewing hundreds of DNA variants to assess their implications for disease. To overcome the variant interpretation bottleneck, clinical laboratories need rapid technological innovation. The next frontier in genomic testing lies in solutions that leverage artificial intelligence (AI) to improve existing processes. AION is the flagship AI-driven platform for rare disease variant interpretation, developed by Nostos Genomics. AION supports analysts to diagnose rare diseases faster using a machine-learning model trained on millions of high-quality genetic variant data points. When applied to cases from the 100,000 genomes project, AION identified the causative variant with a sensitivity of 91.5%, increasing to 93.1% when parental information is provided and 94% in paediatric patients. AION empowers clinical laboratories and genetic testing services to deliver accurate, timely, reproducible variant interpretations for rare disease patients.
In this white paper, we uncover answers to key questions in rare disease genomics:
